Migraine is arguably the most common neurological condition, affecting up to 80% of adults at some time in their lives.

Condition(s) Type of Drug Phase Add-On Placebo Duration Open-Label Extension
Adult episodic migraine preventive Oral Zavegepant III Yes 50% 24 weeks

Response Form

If you or a loved one is interested in participating in one of our trials, please contact us at (855) 829-8899 or use the form below. One of our skilled Clinical Research Coordinators will contact you as soon as possible. Thank you for your interest in our research!

Stephen S. Flitman, MD, Medical Director

Your Name
Name of Patient
Email Address
Your Telephone
Best Time to Call